Update | Ordinary Index Rebalancing in the Solactive Pharma Breakthrough Value Index | March 2021

Update to the announcement from 09.03.2020. In the ordinary rebalance the following updated composition will be implemented effective open 22.03.2021:

ABBVIE INC
ALEXION PHARMACEUTICALS INC
ALNYLAM PHARMACEUTICALS INC
BEIGENE LTD-ADR
BIOGEN INC
BIOMARIN PHARMACEUTICAL INC
BRISTOL-MYERS SQUIBB CO
CHUGAI PHARMACEUTICAL CO LTD ORD
CSL LTD ORD
EISAI
EMERGENT BIOSOLUTIONS INC
GENMAB A/S
GRIFOLS SA CLASS A
HALOZYME THERAPEUTICS INC
HORIZON THERAPEUTICS PLC
INCYTE CORP
IONIS PHARMACEUTICALS INC
IPSEN SA
JAZZ PHARMACEUTICALS PLC
KYOWA KIRIN CO LTD
LIGAND PHARMACEUTICALS INC
NIPPON SHINYAKU CO LTD
NOVARTIS AG
OXFORD BIOMEDICA PLC
PHARMA MAR SA
ROCHE HOLDING AG
SANOFI SA
SAREPTA THERAPEUTICS INC
SEAGEN INC
SINO BIOPHARMACEUTICAL LTD ORD
SWEDISH ORPHAN BIOVITRUM AB
ULTRAGENYX PHARMACEUTICAL INC
UNITED THERAPEUTICS CORP
VERTEX PHARMACEUTICALS INC